Specialists from Dana-Farber/Brigham and Women’s Cancer Center, Dana-Farber Cancer Institute, and Brigham and Women’s Hospital recently introduced the Breast Cancer Personalized Risk Assessment, Education and Prevention (B-PREP) Program for patients at increased risk for breast cancer and for patients who want to better understand their risk. Read More
Dana-Farber/Brigham and Women’s Cancer is one of few centers in the country certified to offer this new approach.
Following a successful clinical trial involving Dana-Farber Cancer Institute and Brigham and Women’s Hospital, the first chimeric antigen receptor (CAR) T-cell therapy for adult cancers was approved by the Food and Drug Administration (FDA) on Oct.19. Dana-Farber/Brigham and Women’s Cancer Center was the only facility in the northeast to be part of the clinical trial that led to FDA approval and is one of a few locations certified to offer this new therapy nationwide. Read More
In a groundbreaking study, experts at Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) showed that a personalized cancer vaccine, which targets neoantigens, stimulated a potent, safe and highly specific anti-tumor response in six patients with melanoma. Read More